[KE peptide regulates SIRT1, PARP1, PARP2 gene expression and protein synthesis in human mesenchymal stem cells aging.]

Khavinson VK, Linkova NS, Ashapkin VV, Shilovsky GA, Borushko NV, Petukhov MG, Vanuyshin BF

Advances in gerontology = Uspekhi gerontologii1 Jan 2023

PMID37782636PepBankPUB-37782636

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

6 results from studies that gave the peptide. No result from this study comes from people.

01LabIn vitro (cells)Mechanism
In young human MSCs, KE peptide increased SIRT1 gene expression sixfold.
In plain wordsIn cells, KE peptide increased SIRT1 gene expression in young human stem cells.
Peptide
Vilon (KE)
Outcome
IncreaseSIRT1 gene expression
Study
humann: not reported in source
Human mesenchymal stem cells
Outcome group
Aging markers · Aging and longevity
Studied dose
Dose not stated
Measurements
SIRT1 gene expression
6 times
young MSCs
Source sentences
Summary
The KE peptide increased gene expression and synthesis of the SIRT1 protein in «young» MSCs by 6 and 8,2 times, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
The aim of this work is to evaluate the effect of the KE peptide on gene expression and protein synthesis of SIRT1, PARP1, PARP2 during aging of human mesenchymal stem cells (MSC).
Report a problemFND-3778263601
02LabIn vitro (cells)Mechanism
In young human MSCs, KE peptide increased SIRT1 protein synthesis 8.2-fold.
In plain wordsIn cells, KE peptide increased SIRT1 protein production in young human stem cells.
Peptide
Vilon (KE)
Outcome
IncreaseSIRT1 protein synthesis
Study
humann: not reported in source
Human mesenchymal stem cells
Outcome group
Aging markers · Aging and longevity
Studied dose
Dose not stated
Measurements
SIRT1 protein synthesis
8.2 times
young MSCs
Source sentences
Summary
The KE peptide increased gene expression and synthesis of the SIRT1 protein in «young» MSCs by 6 and 8,2 times, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
The aim of this work is to evaluate the effect of the KE peptide on gene expression and protein synthesis of SIRT1, PARP1, PARP2 during aging of human mesenchymal stem cells (MSC).
Report a problemFND-3778263602
03LabIn vitro (cells)Mechanism
During human MSC aging, KE peptide reduced PARP1 gene expression 2.1-fold.
In plain wordsIn cells, KE peptide reduced PARP1 gene expression during human stem cell aging.
Peptide
Vilon (KE)
Outcome
DecreasePARP1 gene expression
Study
humann: not reported in source
Human mesenchymal stem cells
Outcome group
Aging markers · Aging and longevity
Studied dose
Dose not stated
Measurements
PARP1 gene expression
2.1 times
MSC aging
Source sentences
Summary
The KE peptide reduced gene expression and PARP1 protein synthesis during MSC aging by 2,1 and 5,3 times, respectively;
1 context sentence(design, population, supporting numbers)
Summary · context
The aim of this work is to evaluate the effect of the KE peptide on gene expression and protein synthesis of SIRT1, PARP1, PARP2 during aging of human mesenchymal stem cells (MSC).
Report a problemFND-3778263603
04LabIn vitro (cells)Mechanism
During human MSC aging, KE peptide reduced PARP1 protein synthesis 5.3-fold.
In plain wordsIn cells, KE peptide reduced PARP1 protein production during human stem cell aging.
Peptide
Vilon (KE)
Outcome
DecreasePARP1 protein synthesis
Study
humann: not reported in source
Human mesenchymal stem cells
Outcome group
Aging markers · Aging and longevity
Studied dose
Dose not stated
Measurements
PARP1 protein synthesis
5.3 times
MSC aging
Source sentences
Summary
The KE peptide reduced gene expression and PARP1 protein synthesis during MSC aging by 2,1 and 5,3 times, respectively;
1 context sentence(design, population, supporting numbers)
Summary · context
The aim of this work is to evaluate the effect of the KE peptide on gene expression and protein synthesis of SIRT1, PARP1, PARP2 during aging of human mesenchymal stem cells (MSC).
Report a problemFND-3778263604
05LabIn vitro (cells)Mechanism
During human MSC aging, KE peptide reduced PARP2 gene expression 2.1-fold.
In plain wordsIn cells, KE peptide reduced PARP2 gene expression during human stem cell aging.
Peptide
Vilon (KE)
Outcome
DecreasePARP2 gene expression
Study
humann: not reported in source
Human mesenchymal stem cells
Outcome group
Aging markers · Aging and longevity
Studied dose
Dose not stated
Measurements
PARP2 gene expression
2.1 times
MSC aging
Source sentences
Summary
The KE peptide reduced gene expression and PARP1 protein synthesis during MSC aging by 2,1 and 5,3 times, respectively; and also reduced gene expression and PARP2 protein synthesis by 2,1 and 4,7 times, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
The aim of this work is to evaluate the effect of the KE peptide on gene expression and protein synthesis of SIRT1, PARP1, PARP2 during aging of human mesenchymal stem cells (MSC).
Report a problemFND-3778263605
06LabIn vitro (cells)Mechanism
During human MSC aging, KE peptide reduced PARP2 protein synthesis 4.7-fold.
In plain wordsIn cells, KE peptide reduced PARP2 protein production during human stem cell aging.
Peptide
Vilon (KE)
Outcome
DecreasePARP2 protein synthesis
Study
humann: not reported in source
Human mesenchymal stem cells
Outcome group
Aging markers · Aging and longevity
Studied dose
Dose not stated
Measurements
PARP2 protein synthesis
4.7 times
MSC aging
Source sentences
Summary
The KE peptide reduced gene expression and PARP1 protein synthesis during MSC aging by 2,1 and 5,3 times, respectively; and also reduced gene expression and PARP2 protein synthesis by 2,1 and 4,7 times, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
The aim of this work is to evaluate the effect of the KE peptide on gene expression and protein synthesis of SIRT1, PARP1, PARP2 during aging of human mesenchymal stem cells (MSC).
Report a problemFND-3778263606

Studies that did not test the peptide alone2

In this study, Vilon (KE) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Vilon (KE).

07Computer modelNot a test of Vilon (KE) aloneIn silicoMechanism
Molecular modeling predicted that KE peptide can interact with GCGG in B-form dsDNA and GGGC in nucleosomal dsDNA.
In plain wordsComputer models predicted that KE peptide can interact with specific DNA sequences.
Peptide
Vilon (KE)
Outcome
Not applicablePredicted DNA sequence interaction
Study
n: not reported in source
Molecular modeling of double-stranded DNA
Outcome group
Receptor activity and mechanism · Pharmacology
Source sentences
Summary
According to molecular modeling data, the KE peptide can interact with the GCGG sequence of double-stranded DNA (dsDNA) in the classical B-form and with the GGGC sequence of the curved dsDNA nucleosome.
In this study, Vilon (KE) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vilon (KE).
Report a problemFND-3778263607
08Computer modelNot a test of Vilon (KE) aloneIn silicoMechanism
The modeled KE-interacting DNA sequences occurred in promoters of human SIRT1, PARP1 and PARP2 genes.
In plain wordsComputer analysis found the predicted KE interaction sequences in human gene promoters.
Peptide
Vilon (KE)
Outcome
Not applicableDNA interaction sequences in gene promoters
Study
humann: not reported in source
Human gene promoters
Outcome group
Receptor activity and mechanism · Pharmacology
Source sentences
Summary
The indicated dsDNA sequences were found in the promoters of the human SIRT1, PARP1, PARP2 genes.
1 context sentence(design, population, supporting numbers)
Summary · context
According to molecular modeling data, the KE peptide can interact with the GCGG sequence of double-stranded DNA (dsDNA) in the classical B-form and with the GGGC sequence of the curved dsDNA nucleosome.
In this study, Vilon (KE) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vilon (KE).
Report a problemFND-3778263608

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
21 Oct 2026, 17:05 UTC
Study results updated
Version 1
21 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.